X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1295) 1295
Publication (94) 94
Book Review (38) 38
Newsletter (27) 27
Magazine Article (11) 11
Book Chapter (9) 9
Book / eBook (2) 2
Conference Proceeding (2) 2
Newspaper Article (1) 1
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
levetiracetam (1151) 1151
epilepsy (645) 645
index medicus (611) 611
humans (600) 600
piracetam - analogs & derivatives (547) 547
pharmacology & pharmacy (488) 488
male (480) 480
clinical neurology (439) 439
anticonvulsants - therapeutic use (389) 389
animals (372) 372
seizures (364) 364
female (361) 361
antiepileptic drugs (336) 336
anticonvulsants - pharmacology (306) 306
anticonvulsants (276) 276
piracetam - pharmacology (260) 260
piracetam - therapeutic use (254) 254
epilepsy - drug therapy (243) 243
neurosciences (237) 237
adult (231) 231
rats (215) 215
neurology (214) 214
anticonvulsants - adverse effects (195) 195
double-blind (192) 192
middle aged (186) 186
analysis (176) 176
drug therapy (176) 176
dose-response relationship, drug (169) 169
lamotrigine (147) 147
anticonvulsants - administration & dosage (145) 145
pharmacokinetics (145) 145
treatment outcome (141) 141
children (137) 137
efficacy (135) 135
carbamazepine (134) 134
drugs (132) 132
adolescent (129) 129
piracetam - adverse effects (129) 129
topiramate (126) 126
seizures - drug therapy (125) 125
phenytoin (123) 123
disease models, animal (122) 122
piracetam - administration & dosage (122) 122
medicine & public health (120) 120
antiepileptic drug levetiracetam (119) 119
mice (117) 117
aged (115) 115
dosage and administration (114) 114
anticonvulsants - pharmacokinetics (104) 104
research (102) 102
antiepileptic drug (100) 100
child (100) 100
brain (94) 94
status epilepticus (94) 94
complications and side effects (93) 93
psychiatry (91) 91
care and treatment (89) 89
tolerability (89) 89
valproic acid (89) 89
rats, sprague-dawley (88) 88
ucb l059 (88) 88
young adult (86) 86
oxcarbazepine (82) 82
temporal-lobe epilepsy (82) 82
gabapentin (80) 80
risk factors (79) 79
drug therapy, combination (77) 77
etiracetam (76) 76
drug interactions (75) 75
pharmacology (75) 75
piracetam - pharmacokinetics (74) 74
refractory partial seizures (73) 73
pharmacology/toxicology (71) 71
profile (69) 69
rats, wistar (69) 69
health aspects (68) 68
therapy (68) 68
electroencephalography (67) 67
placebo-controlled trial (67) 67
partial-onset seizures (65) 65
pharmacotherapy (65) 65
safety (65) 65
toxicology (65) 65
models (64) 64
valproate (64) 64
hippocampus - drug effects (62) 62
zonisamide (62) 62
retrospective studies (61) 61
time factors (61) 61
pediatrics (59) 59
partial seizures (58) 58
anticonvulsant (57) 57
add-on therapy (56) 56
binding-site (56) 56
internal medicine (56) 56
epilepsies, partial - drug therapy (55) 55
rat (55) 55
anticonvulsants - blood (54) 54
medical research (54) 54
multicenter (53) 53
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1329) 1329
French (4) 4
German (4) 4
Japanese (4) 4
Spanish (3) 3
Croatian (1) 1
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neuroscience Letters, ISSN 0304-3940, 01/2003, Volume 335, Issue 3, pp. 167 - 170
Some anticonvulsants show neuroprotective effects, and may be of use in reducing neuronal death resulting from stroke or traumatic brain injury. Here I report... 
Oxygen/glucose deprivation | Hippocampal slice cultures | Neuroprotection | Anticonvulsants | OXYGEN | INHIBITION | IN-VITRO ISCHEMIA | neuroprotection | DRUGS | hippocampal slice cultures | oxygen/glucose deprivation | GLUCOSE DEPRIVATION | anticonvulsants | NEUROSCIENCES | DAMAGE | Phenobarbital - pharmacology | Hypoxia - drug therapy | Amines | Felbamate | Gabapentin | Rats, Wistar | Phenylcarbamates | Anticonvulsants - administration & dosage | Hippocampus - drug effects | Anticonvulsants - pharmacology | Valproic Acid - pharmacology | Hypoxia - metabolism | Dose-Response Relationship, Drug | Oxcarbazepine | Tiagabine | Neuroprotective Agents - pharmacology | Piracetam - pharmacology | Phenytoin - pharmacology | Chlordiazepoxide - pharmacology | Neurons - metabolism | Cell Death - drug effects | Neurons - drug effects | Neuroprotective Agents - administration & dosage | Nipecotic Acids - pharmacology | Carbamates - pharmacology | Propylene Glycols - pharmacology | gamma-Aminobutyric Acid | Carbamazepine - pharmacology | Triazines - pharmacology | Carbamazepine - analogs & derivatives | Cells, Cultured | Ischemia - metabolism | Rats | Hippocampus - cytology | Glucose - deficiency | Hippocampus - metabolism | Animals | Ischemia - drug therapy | Piracetam - analogs & derivatives | Phenylenediamines - pharmacology | Acetates - pharmacology | Cyclohexanecarboxylic Acids | Ethosuximide - pharmacology | Midazolam - pharmacology | Lamotrigine | Levetiracetam | Brain | Cell death | Injuries | Stroke (Disease)
Journal Article
Journal of Biochemical and Molecular Toxicology, ISSN 1095-6670, 06/2017, Volume 31, Issue 6, p. n/a
Serum paraoxonase (PON1) is a key enzyme related to high‐density lipoprotein (HDL)‐cholesterol particle. It can prevent the oxidation of low‐density... 
paraoxonase | enzyme purification | antiepileptic drug, enzyme inhibition | OXIDATIVE STRESS | PROTEIN | antiepileptic drug | HUMAN PLASMA | BIOCHEMISTRY & MOLECULAR BIOLOGY | LOW-DENSITY-LIPOPROTEIN | ATHEROSCLEROSIS | IN-VITRO | enzyme inhibition | UNKNOWN QUANTITY | TOXICOLOGY | EPILEPSY | ARYLESTERASE ACTIVITY | LEVETIRACETAM | Aryldialkylphosphatase - blood | Humans | Piracetam - adverse effects | Anticonvulsants - pharmacology | Valproic Acid - pharmacology | Anticonvulsants - adverse effects | Aryldialkylphosphatase - antagonists & inhibitors | Piracetam - pharmacology | Primidone - pharmacology | Phenytoin - pharmacology | Amines - adverse effects | Valproic Acid - adverse effects | gamma-Aminobutyric Acid - adverse effects | Enzyme Inhibitors - adverse effects | Primidone - adverse effects | Aryldialkylphosphatase - isolation & purification | Cyclohexanecarboxylic Acids - adverse effects | Enzyme Inhibitors - pharmacology | gamma-Aminobutyric Acid - pharmacology | Aryldialkylphosphatase - metabolism | Turkey | Cyclohexanecarboxylic Acids - pharmacology | Phenytoin - adverse effects | Piracetam - analogs & derivatives | Kinetics | Amines - pharmacology | Enzymes | Anticonvulsants | Chromatography | Drugs | Lipoproteins (low density) | Gabapentin | Paraoxonase | Valproic acid | Antiepileptic agents | Etiracetam | Low density lipoprotein | Cholesterol | Acids | Oxidation | Inhibition | Lipoproteins (high density) | In vitro methods and tests | Phenytoin | Index Medicus
Journal Article
Frontiers in Neurology, ISSN 1664-2295, 2013, Volume 4, p. 192
Status epilepticus and acute repetitive seizures still pose a management challenge despite the recent advances in the field of epilepsy. Parenteral... 
Pharmacokinetics | Epilepsy | Levetiracetam | epilepsy | pharmacokinetics | NEUROSCIENCES | CLINICAL NEUROLOGY | levetiracetam | Status Epilepticus | Seizures
Journal Article
Journal Article
Journal Article
Neuroscience, ISSN 0306-4522, 2013, Volume 250, pp. 536 - 545
Journal Article
Journal Article
Seizure: European Journal of Epilepsy, ISSN 1059-1311, 2015, Volume 31, pp. 133 - 140
Journal Article
Neuropharmacology, ISSN 0028-3908, 2003, Volume 45, Issue 5, pp. 661 - 671
Journal Article